Key result
DDX3 acts as a double-edged sword in the host immune response and viral replication, serving as a promising target for anticancer and antiviral treatments.
Why the study?
Increasing evidence suggests DDX3 is a promising, viable target for anticancer and antiviral treatments, playing a dual role in viral replication and host immune response.
Design
Review
Authors
Loading...
DDX3 modulation merits cautious preclinical study; leaves open context-specific targeting strategies for cancer and viral disease.
DDX3 is a promising target for antiviral and anticancer therapies due to its dual role in host immune response and viral replication.
Hernández‐Díaz et al. (2021) conducted a review in Viral infection and cancer. DDX3 was evaluated. DDX3 acts as a double-edged sword in the host immune response and viral replication, serving as a promising target for anticancer and antiviral treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: